Pentixapharm Advances Phase 3 PANDA Study in Primary Aldosteronism

Pentixapharm Holding AG, a biotech company based in Berlin, reports significant progress in its Phase 3 PANDA study on primary aldosteronism. Research from Europe and Asia confirms Pentixafor PET's high specificity in identifying unilateral primary aldosteronism, supporting the study's rationale. The study aims to replace invasive adrenal vein sampling with non-invasive subtyping, helping to determine surgical versus medical treatment in hypertensive patients.

FDA approved the PANDA study and granted Fast Track designation. Preparations continue in the U.S., while international studies bolster evidence for Pentixafor PET's effectiveness. The PENTALON study in Paris and the Monash study in Australia validate its specificity and patient preference over traditional catheter procedures.